RESOURCES

Resources

Medical Journals

Research Publications

Research Initiatives

CBD Medical Research

Research by Condition

  • Andries, A., Frystyk, J., Flyvbjerg, A., and Stoving, RK. (2015, July). Changes in IGF-I, urinary free cortisol and adipokines during dronabinol therapy in anorexia nervosa: Results from a randomised, controlled trial. Growth Hormone & IGF Research, (15), 30017-4. Retrieved from http://www.growthhormoneigfresearch.com/article/S1096-6374(15)30017-4/fulltext.
  • Andries, A., Frystyk, J., Flyvbjerg, A., and Stoving, R.K. (2014, January). Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. The International Journal of Eating Disorders, (47)1, 18-23. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1002/eat.22173/full.
  • Andries, A., Gram, B., and Stoving, R.K. (2015, March). Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial. Eating and Weight Disorders, 20(1), 13-21. Retrieved from http://link.springer.com/article/10.1007%2Fs40519-014-0132-5.
  • Anorexia Nervosa. (n.d.). NEDA. Retrieved from https://www.nationaleatingdisorders.org/anorexia-nervosa.
  • Beal, J.E., Olson, R., Laubenstein, L., Morales, J.O., Bellman, P., Yangco, B., Lefkowitz, L, Plasse, T.F. and Shephard, K.V. (1995, February). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and System Management, 10(2), 89-97. Retrieved from http://www.jpsmjournal.com/article/0885-3924(94)00117-4/pdf.
  • Cota, D., Marsicano, G., Lutz, B., Vicennati, V., Stalla, G.K., Pasquali, R., and Pagotto, U. (2013, March). Endogenous cannabinoid system as a modulator of food intake. International Journal of Obesity and Related Metabolic Disorders, 27(3), 289-301. Retrieved from http://www.nature.com/ijo/journal/v27/n3/full/0802250a.html.
  • Koch, M., Varela, L., Geun Kim, J., Dae Kim, J., Hernández-Nuño, F., Simonds, S.E., Castorena, C.M., Vianna, C.R., Elmquist, J.K., Morozov, Y.M., Rakic, P., Bechmann, I., Cowley, M.A., Szigeti-Buck, K., Dietrich, M.L., Gao, X.-B., Diano, S., and Horvath, T.L. (2015, March 5). Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature, 519, 45-50. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496586/.
  • Mechoulam, R., Berry, E.M., Avraham, Y., Di Marzo, V., and Fride, E. (2006). Endocannabinoids, feedling and suckling – from our perspective. International Journal of Obesity, 30, S24-S28. Retrieved from http://www.nature.com/ijo/journal/v30/n1s/full/0803274a.html.
  • Scherma, M., Fattore, L., Castelli, M.P., Fratta, W., and Fadda, P. (2014). The role of the endocannabinoid system in eating disorders: neurochemical and behavioural preclinical evidence. Current Pharmaceutical Design, 20(13), 2089-99. Retrieved from http://www.eurekaselect.com/111826/article

Real life Experience of Medical Cannabis Treatment in Autism- Analysis of Safety and Efficacy www.nature.com/scientificreports Lihi Bar-Lev Schleider, Raphael Mechoulam, Naama Saban, Gal Meiri & Victor Novack. Jan 19, 2019

  • Abrams, D.I., Jay, C.A., Shade, S.B., Vizoso, H., Reda, H., Press, S., Kelly, M.E., Rowbotham, M.C., and Petersen, K.L. (2007, February). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68(7), 515-21. Retrieved from http://safeaccess.ca/research/pdf/hiv_pain_cannabis_abrams.pdf.
  • Andries, A., Gram, B. and Stoving, RK. (2015, March). Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial. Eating and Weight Disorders, 20(1), 13-21. Retrieved from http://link.springer.com/article/10.1007%2Fs40519-014-0132-5.
  • Beal, J.E., Olson, R., Laubenstein, L., Morales, J.O., Bellman, P., Yangco, B., Lefkowitz, L, Plasse, T.F., and Shephard, KV. (1995, February). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and System Management, 10(2), 89-97. Retrieved from http://www.jpsmjournal.com/article/0885-3924(94)00117-4/pdf.
  • Cachexia (n.d.). Patient. Retrieved from http://patient.info/doctor/cachexia.
  • Cota, D., Marsicano, G., Lutz, B., Vicennati, V., Stalla, G.K., Pasquali, R., and Pagotto, U. (2003). Endogenous cannabinoid system as a modulator of food intake. International Journal of Obesity, 27, 289-301. Retrieved from http://www.nature.com/ijo/journal/v27/n3/full/0802250a.html.
  • Jatoi, A., Windschitl, H.E., Loprinzi, C.L., Sloan, J.A., Dakhil, S.R., Mailliard, J.A., Pundaleeka, S., Kardinal, C.G., Fitch, T.R., Krook, J.E., Novotny, P.J., and Christensen, B. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology, 20(2), 567-73. Retrieved from http://ascopubs.org/doi/full/10.1200/JCO.2002.20.2.567.
  • Koch, M., Varela, L., Geun Kim, J., Dae Kim, J., Hernández-Nuño, F., Simonds, S.E., Castorena, C.M., Vianna, C.R., Elmquist, J.K., Morozov, Y.M., Rakic, P., Bechmann, I., Cowley, M.A., Szigeti-Buck, K., Dietrich, M.L., Gao, X.-B., Diano, S., and Horvath, T.L. (2015, March 5). Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature, 519, 45-50. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496586/.
  • Mechoulam, R., Berry, E.M., Avraham, Y., Di Marzo, V., and Fride, E. (2006). Endocannabinoids, feeding and sucking – from our perspective. International Journal of Obesity, 30, S24-S28. Retrieved from http://www.nature.com/ijo/journal/v30/n1s/full/0803274a.html
  • Nauck, F., Klaschik,E. (2004, June). Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients. Schmerz, 18(3), 197-202. Retrieved from http://link.springer.com/article/10.1007%2Fs00482-003-0277-z.
  • What causes Cancer Cachexia? (n.d.). Cancer Cachexia Hub. Retrieved from http://www.cancercachexia.com/what-causes-cancer-cachexia.
  • Benz, A. H., Renné, C., Maronde, E., Koch, M., Grabiec, U., Kallendrusch, S., Rengstl, B., Newrzela, S., Hartmann, S., Hansmann, M.L., and Dehghani, F. (2013). Expression and Functional Relevance of Cannabinoid Receptor 1 in Hodgkin Lymphoma. PLoS ONE8(12), e81675. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857220/?report=reader.
  • Blázquez, C., Casanova, M.L., Planas, A., Gómez Del Pulgar, T., Villanueva, C., Fernández-Aceñero, M.J., Aragonés, J., Huffman, J.W., Jorcano, J.L., Guzmán, M. (2003, March). Inhibition of tumor angiogenesis by cannabinoids. FASEB Journal, 17(3), 529-31. Retrieved from http://www.fasebj.org/content/early/2003/03/02/fj.02-0795fje.long.
  • Blazquez, C., Gonzalez-Feria, L., Alvarez, L., Haro, A., Casanova, M.L., and Guzman, M. (2004, August 15). Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Research, 64(16), 5617-23. Retrieved from http://cancerres.aacrjournals.org/content/64/16/5617.long.
  • Blázquez, C., Carracedo, A., Barrado, L., Real, P.J., Fernández-Lun, J.L., Velasco, G., Malumbres, M., and Guzmán, M. (2006, December) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB Journal, 20(14), 2633-5. Retrieved from http://www.fasebj.org/content/20/14/2633.long.
  • Brisbois, T.D., de Kock, I.H., Watanabe, S.M., Mirhosseini, M., Lamoureux, D.C., Chasen, M., MacDonald, N., Baracos, V.E., and Wismer, W.V. (2011, February 22). Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized-double-blind, placebo-controlled pilot trial. Annals of Oncology, 22, 2086-2093. Retrieved from https://academic.oup.com/annonc/article/22/9/2086/211788/Delta-9-tetrahydrocannabinol-may-palliate-altered.
  • Caffarel, M. M., Andradas, C., Mira, E., Pérez-Gómez, E., Cerutti, C., Moreno-Bueno, G., Flores, J.M., Garcia-Real, I., Palacios, J., Manes, S., Guzman, M., and Sánchez, C. (2010). Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer, 9, 196. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917429/.
  • Carracedo, A., Lorente, M., Egia, A., Blázquez, C., García, S., Giroux, V., Malicet, C., Villuendas, R., Gironella, M., González-Feria, L., Piris, M.A., Iovanna, J.L., Guzmán, M., Velasco, G. (2006, April). The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell, 9(4), 301-12. Retrieved from http://www.cell.com/cancer-cell/fulltext/S1535-6108(06)00085-7.
  • Casanova, M.L., Blázquez, C., Martínez-Palacio, J., Villanueva, C., Fernández-Aceñero, M.J., Huffman, J.W., Jorcano, J.L., and Guzmán, M. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation111(1), 43–50. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151833/.
  • Cudaback, E., Marrs, W., Moeller, T., and Stella, N. (2010). The Expression Level of CB1 and CB2Receptors Determines Their Efficacy at Inducing Apoptosis in Astrocytomas. PLoS ONE5(1), e8702. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806825/.
  • De Petrocellis, L., Melck, D., Palmisano, A., Bisogno, T., Laezza, C., Bifulco, M., and Di Marzo, V. (1998). The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 95(14), 8375–8380. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC20983/.
  • Estimated Number of New Cancer Cases and Deaths by Sex, US, 2015. (2015). American Cancer Society. Retrieved from http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044514.pdf.
  • Galve-Roperh, I., Sanchez, C., Cortes, M.L., Gomez del Pulgar, T., Izquiero, M., and Guzman, M. (2000, March). Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine, 6(3), 313-9. Retrieved from http://www.nature.com/nm/journal/v6/n3/full/nm0300_313.html.
  • Glodde, N., Jakobs, M., Bald, T., Tuting, T., and Gaffal, E. (2015, October 1). Differential role of cannabinoids in the pathogenesis of skin cancer. Life Sciences, 138, 35-40. Retrieved from http://www.sciencedirect.com/science/article/pii/S0024320515002209.
  • Gómez Del Pulgar, T., De Ceballos, M.L., Guzmán, M., and Velasco, G. (2002, September). Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway. The Journal of Biological Chemistry, 277(30), 36527-33. Retrieved from http://www.jbc.org/content/277/39/36527.long.
  • Gustafsson, K., Christensson, B., Sander, B., and Fiygare, J. (2006, November). Cannabinoid Receptor-Mediated Apoptosis Induced by R(+)-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma. Molecular Pharmacology, 70(5), 1612-20. Retrieved from http://molpharm.aspetjournals.org/content/70/5/1612.long.
  • Gustafsson, K., Wang, X., Severa, D., Eriksson, M., Kimby, E., Merup, M., Christensson, B., Flygare, J., and Sander, B. (2008, September 1). Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. International Journal of Cancer, 123(5), 1025-33. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/ijc.23584/full.
  • Gustafsson, K., Sander, B., Bielawski, J., Hannun, Y.A., and Flygare, J. (2009). Potentiation of cannabinoid-induced cytotoxicity in Mantle Cell Lymphoma through modulation of ceramide metabolism. Molecular Cancer Research : MCR7(7), 1086–1098. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077284/.
  • Guzmán, M., Duarte, M.J., Blázquez, C., Ravina, J., Rosa, M.C., Galve-Roperh, I., Sanchez, C., Velasco, G., and González-Feria, L. (2006). A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer, 95(2), 197–203. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360617/.
  • Guzmán, M., Galve-Roperh, I., and Sánchez, C. (2001, January). Ceramide: a new second messenger of cannabinoid action. Trends in Pharmacological Sciences, 22(1), 19-22. Retrieved from http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(00)01586-8.
  • Hamtiaux, L., Hansoulle, L., Dauguet, N., Muccioli, G.G., Gallez, B., and Lambert, D.M. (2011). Increasing Antiproliferative Properties of Endocannabinoids in N1E-115 Neuroblastoma Cells through Inhibition of Their Metabolism. PLoS ONE6(10), e26823. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203169/.
  • Hashibe, M., Morgenstern, H., Cui, Y., Tashkin, D.P., Zhang, Z.F., Cozen, W., Mack, T.M., and Greenland, S. (2006, October). Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiology: Biomarkers & Prevention, 15(10), 1829-34. Retrieved from http://cebp.aacrjournals.org/content/15/10/1829.long.
  • Hernán Pérez de la Ossa, D., Gil-Alegre, M.E., Ligresti, A., del Rosario Aberturas, M., Molpeceres, J., Torres, A.I., and Di Marzo, V. (2013). Preparation and characterisation of biodegradable microparticles filled with THC and their antitumor efficacy on cancer cell lines. Journal of Drug Targeting, early online, 1-9. Retrieved from http://www.tandfonline.com/doi/full/10.3109/1061186X.2013.809089?needAccess=true.
  • Herrera, B., Carracedo, A., Diez-Zaera, M., Gomez del Pulgar, T., Guzman, M., and Velasco, G. (2006, July 1). The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Experimental Cell Research, 312(11), 2121-31. Retrieved from http://www.sciencedirect.com/science/article/pii/S0014482706001066.
  • Islam, T.C., Asplund, A.C., Lindvall, J.M., Nygren, L., Liden, J., Kimby, E., Christensson, B., Smith, C.I., Sander B. (2003, September). High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia, 17(9), 1880-90. Retrieved from http://www.nature.com/leu/journal/v17/n9/full/2403057a.html.
  • Jatoi, A., Windschitl, H.E., Loprinzi, C.L., Sloan, J.A., Dakhil, S.R., Mailliard, J.A., Pundaleeka, S., Kardinal, C.G., Fitch, T.R., Krook, J.E., Novotny, P.J. and Christensen, B. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology, 20(2), 567-73. Retrieved from http://ascopubs.org/doi/full/10.1200/JCO.2002.20.2.567.
  • Lakiotaki, E., Giaginis, C., Tolia, M., Alexandrou, P., Delladetsima, I., Giannopoulou, I., Kyrgias, G. Patsouris, E.., and Theocharis, S. (2015). Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions. BioMed Research International2015, 839403. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619873/.
  • Limebeer, C.L., and Parker, L.A. (1999, December 16). Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport, 10(19), 3769-72. Retrieved from http://journals.lww.com/neuroreport/pages/articleviewer.aspx?year=1999&issue=12160&article=00009&type=abstract.
  • Machado Rocha, F.C., Stefano, S.C., De Cassia Haiek, R., Rosa Oliveira, L.M., and Da Silveira, D.X. (2008, September). Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer Care, 17(5), 431-43. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2354.2008.00917.x/full.
  • McAllister S.D., Chan, C., Taft, R.J., Luu, T., Abood, M.E., Moore, D.H., Aldape, K., and Yount, G. (2005, August). Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. Journal of Neuro-oncology, 74(1), 31-40. Retrieved from http://link.springer.com/article/10.1007%2Fs11060-004-5950-2.
  • McKallip, R.J., Lombard, C., Fisher, M., Martin, B.R., Ryu, S., Grant, S., Nagarkatti, P.S., and Nagarkatti, M. (2002, July 15). Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood, 100(2), 627-34. Retrieved from http://www.bloodjournal.org/content/100/2/627.long?sso-checked=true.
  • Montalbano, R., Honrath, B., Wissniowski, T. T., Elxnat, M., Roth, S., Ocker, M., Quint, K., Churin, Y, Roederfeld, M., Schroeder, D., Glebe, D., Roeb, E., and Fazio, P. D. (2016). Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells. Oncotarget7(15), 20312–20323. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991457/.
  • Moreno, E., Andradas, C., Medrano, M., Caffarel, M. M., Pérez-Gómez, E., Blasco-Benito, S., Gómez-Cañas, M., Pazos, M.R., Irving, A.J., Lluís, C., Canela, E.I., Fernández-Ruiz, J., Guzmán, M., McCormick, P.J., Sánchez, C. (2014). Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling. The Journal of Biological Chemistry289(32), 21960–21972. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139213/.
  • Nakajima, J., Nakae, D., and Yasukawa, K. (2013, August). Structure-dependent inhibitory effects of synthetic cannabinoids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and skin tumour promotion in mice. Journal of Pharmacy and Pharmacology, 65(8), 1223-1230. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1111/jphp.12082/full.
  • National Toxicology Program. (1996, November). NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Technical Report Series, 446, 1-317. Retrieved from https://ntp.niehs.nih.gov/results/pubs/longterm/reports/longterm/tr400499/abstracts/tr446/index.html.
  • Niu, F., Zhao, S., Xu, C.Y., Sha, H., Bi, G.B., Chen, L., Ye, L., Gong, P., and Nie, T.H. (2015). Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2. Oncology Letters, 10(4), 2415–2421. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580018/.
  • Oesch, S., Walter ,D., Wachtel, M., Pretre, K., Salazar, M., Guzmán, M., Velasco, G., and Schäfer, B.W. (2009, July). Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Molecular Cancer Therapy, 8(7), 1838-45. Retrieved from http://mct.aacrjournals.org/content/8/7/1838.long.
  • Orellana-Serradell, O., Poblete, C.E., Sanchez, C., Castellon, E.A., Gallegos, I., Huidobro, C., Llanos, M.N., and Contreras, H.R. (2015, April). Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncology Reports, 33(4), 1599-608. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358087/.
  • Pisanti, S., Borselli, C., Oliviero, O., Laezza, C., Gazzerro, P., Bifulco, M. (2007, May). Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. Journal of Cellular Physiology, 211(2), 495-503. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcp.20954/full.
  • Preet, A., Ganju, R.K.., and Groopman, J.E. (2008, January). Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene, 27(3), 339-46. Retrieved from http://www.nature.com/onc/journal/v27/n3/full/1210641a.html.
  • Qamri, Z., Preet, A., Nasser, M.W., Bass, C.E., Leone, G., Barsky, S.H., and Ganju, R.K. (2009). Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Molecular Cancer Therapeutics, 8(11), 3117–3129. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128286/.
  • Ramer, R., and Hinz, B. (2008, January). Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1. Journal of the National Cancer Institute, 100(1), 59-69. Retrieved from https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djm268.
  • Ramos, J.A., and Bianco, F.J. (2012). The role of cannabinoids in prostate cancer: cBasic science perspective and potential clinical applications. Indian Journal of Urology : IJU : Journal of the Urological Society of India28(1), 9–14. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751914/.
  • Salazar, M., Carracedo, A., Salanueva, Í.J., Hernández-Tiedra, S., Lorente, M., Egia, A., Vazquez, P., Blazquez, C., Torres, S., Garcia, S., Nowak, J., Fimia, G.M., Piacentini, M., Cecconi, F., Pandolfi, P.P., Gonzalez-Feria, L., Iovanna, J.L., Guzman, M., Boya, P., and Velasco, G. (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. The Journal of Clinical Investigation, 119(5), 1359–1372. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673842/.
  • Sallan, S.E., Zinberg, N.E., and Frei, E. (1975, October 16). Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy. The New England Journal of Medicine, 293(16), 795-7. Retrieved from http://www.nejm.org/doi/full/10.1056/NEJM197510162931603.
  • Sanchez, C., de Ceballos, M.L., Gomez del Pulgar, T., Rueda, D., Corbacho, C. Velasco, G., Galve-Roperh, I., Huffman, J.W., Ramon y Cajal, S., and Guzman, M. (2001, August 1). Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Research, 61(15), 5784-9. Retrieved from http://cancerres.aacrjournals.org/content/61/15/5784.long
  • Thomas, A.A., Wallner, L.P., Quinn, V.P., Slezak, J., Van Den Eeden, S.K., Chien, G.W., and Jacobsen, S.J. (2015, February). Association between cannabis use and the risk of bladder cancer: results from the California Men’s Health Study. Urology, 85(2), doi: 10.1016/j.urology.2014.08.060. Epub 2014 Nov 1. Retrieved from http://www.sciencedirect.com/science/article/pii/S0090429514012060.
  • Van Dross, R., Soliman, E., Jha, S., Johnson, T., and Mukhopadhyay, S. (2013). Receptor-dependent and Receptor-independent Endocannabinoid Signaling: A Therapeutic Target for Regulation of Cancer Growth. Life Sciences92(0), 463–466. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226396/.
  • Vara, D., Salazar, M., Olea-Herrero, N., Guzmán, M., Velasco, G., and Díaz-Laviada, I. (2011). Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death and Differentiation, 18(7), 1099–1111. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131949/.
  • Vara, D., Morell, C., Rodríguez-Henche, N., and Diaz-Laviada, I. (2013). Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell Death & Disease4(5), e618–. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674350/.
  • Velasco, G., Galve-Roperh, I., Sánchez, C., Blázquez, C., Haro, A., and Guzmán, M. (2005, August 19). Cannabinoids and ceramide: two lipids acting hand-by-hand. Life Sciences, 77(14), 1723-31. Retrieved from http://www.sciencedirect.com/science/article/pii/S0024320505005035
  • Wang, D., Wang, H., Ning, W., Backlund, M.G., Dey, S.K., and DuBois, R.N. (2008). Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Research68(15), 6468–6476. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561258/.
  • What Is Cancer? (2015, April 15). American Cancer Society. Retrieved from http://www.cancer.org/cancer/cancerbasics/what-is-cancer.
  • What Is Cancer? (2015, February 9). National Cancer Institute. Retrieved from http://www.cancer.gov/about-cancer/what-is-cancer.
  • Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., and Donaghe, H. (2013, February). Low-dose vaporized cannabis significantly improves neuropathic pain. The Journal of Pain, 14(2), 136-48. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566631/.
  • Xian, X.S., Park, H., Choi, M.G., and Park, J.M (2013, June) Cannabinoid Receptor Agonist as an Alternative Drug in 5-Fluorouracil-resistant Gastric Cancer Cells. Anticancer Research, 33(6), 2541-7. Retrieved from http://ar.iiarjournals.org/content/33/6/2541.long.
  • Xie, C., Liu, G., Liu, J., Huang, Z., Wang, F., Lei, X., Wu, X., Huang, S., Zhong, D., and XU, X. (2012). Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells. Oncology Letters, 4(3), 403–407. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439105/.
  • Zhang, J., Medina-Cleghorn, D., Bernal-Mizrachi, L., Bracci, P.M., Hubbard, A., Conde, L., Riby, J., Nomura, D.K., and Skibola, C. F. (2016). The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. Oncoscience3(1), 31–41. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751914/.
  • Acharya, N., Penukonda, S., Shcheglova, T., Hagymasi, A.T., Basu, S., and Srivastava, P.K. (2017, March 27). Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proceedings of the National Academy of Sciences of the United States, 114(19), 5005-5010. Retrieved from http://www.pnas.org/content/114/19/5005.full.
  • Adhikary, S., Li, H., Heller, J., Skarica, M., Zhang, M., Ganea, D., and Tuma, R.F. (2011). Modulation of Inflammatory Responses by a Cannabinoid-2–Selective Agonist after Spinal Cord Injury. Journal of Neurotrauma28(12), 2417–2427. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235339/.
  • Buchweitz, JP., Karmaus, PW., Williams, KJ., Harkema, JR. and Kaminski, NE. (2008, March). Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence of presence of Delta9-tetrahydrocannabinol. Journal of Leukocyte Biology, 83(3), 785-96. Retrieved from http://www.jleukbio.org/content/83/3/785.long.
  • Clayton, N., Marshall, FH., Bountra, C., and O’Shaughnessy, CT. (2002, April). CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain, 96(3), 253-60. Retrieved from http://journals.lww.com/pain/pages/articleviewer.aspx?year=2002&issue=04000&article=00005&type=abstract.
  • Craft, R.M., Kandasamy, R., and Davis, S.M. (2013, September). Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ9-tetrahydrocannabinol in the rat. Pain, 154(9), 1709-17. Retrieved from http://journals.lww.com/pain/pages/articleviewer.aspx?year=2013&issue=09000&article=00028&type=abstract.
  • Croxford, J.L., and Yamamura, T. (2005, September). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? Journal of Neuroimmunology, 166(1-2), 3-18. Retrieved from http://www.jni-journal.com/article/S0165-5728(05)00160-8/fulltext.
  • De Laurentiis, A., Araujo, H.A., and Rettori, V. (2014). Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation. Current Pharmaceutical Design, 20(29), 4697-706. Retrieved from http://www.eurekaselect.com/120077/article.
  • De Petrocellis, L., Melck, D., Bisogno, T., and Di Marzo, V. (2000, November). Endocannabinoids and fatty acid amides in cancer inflammation and related disorders. Chemistry and Physics of Lipids, 108(1-2), 191-209. Retrieved from http://www.sciencedirect.com/science/article/pii/S0009308400001961.
  • Fimiani, C., Liberty, T., Aquirre, AJ., Amin, I., Ali, N. and Stefano, GB. (1999, January). Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins & Other Lipid Mediators, 57(1), 23-34. Retrieved from http://www.sciencedirect.com/science/article/pii/S0090698098000689.
  • Fukuda, S., Kohsaka, H., Takayasu, A., Yokoyama, W., Miyabe, C., Miyabe, Y., Harigai, M., Miyasaka, N., and Nanki, T. (2014). Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskeletal Disorders15, 275. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243420/.
  • Kinsey, S.G., Mahadevan, A., Zhao, B., Sun, H., Naidu, P.S., Razdan, R.K., Selley, D.E., Imad Damaj, M., and Lichtman, A.H. (2011). The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology60(2-3), 244–251. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021987/.
  • Klein, T.W. (2005, May). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology, 5, 400-411. Retrieved from http://www.nature.com/nri/journal/v5/n5/full/nri1602.html.
  • Matthews, A.T., and Ross, M.K. (2015). Oxyradical Stress, Endocannabinoids, and Atherosclerosis. Toxics3(4), 481–498. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686160/.
  • Michalski, C.W., Maier, M., Erkan, M., Sauliunaite, D., Bergmann, F., Pacher, P., Batkai, S., Giese, N.A., Giese, T., Friess, H., and Kleeff, J. (2008). Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells. PLoS ONE3(2), e1701. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2253501/.
  • Panikashvili, D., Shein, N.A., Mechoulam, R., Trembovler, V, Kohen, R., Alexandrovich, A. and Shohami, E. (2006, May). The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiology of Disease, 22(2), 257-264. Retrieved from http://www.sciencedirect.com/science/article/pii/S0969996105003074.
  • Parker, J., Atez, F., Rossetti, R.G., Skulas, A., Patel, R., and Zurier, R.B. (2008, May). Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatology International, 28(7), 631-5. Retrieved from http://link.springer.com/article/10.1007%2Fs00296-007-0489-0.
  • Wright, K.L., Duncan, M., and Sharkey, K.A. (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. British Journal of Pharmacology, 153(2), 263–270. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219529/.
 
  • Blázquez, C., Chiarlone, A., Bellocchio, L., Resel, E., Pruunsild, P., García-Rincón, D., Sendtner, M., Timmusk, T., Lutz, B., Galve-Roperh, I., and Guzmán, M. (2015). The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death and Differentiation22(10), 1618–1629. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563779/.
  • Castelli, M.P., Madeddu, C., Casti, A., Casu, A., Casti, P., Scherma, M., Fattore, L., Fadda, P., and  Ennas, M.G. (2014). Δ9-Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity. PLoS ONE9(5), e98079. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028295/.
  • Fernández-Ruiz, J., Romero, J., Velasco, G., Tolon, R.M., Ramos, J.A., and Guzman, M. (2007, January). Cannabinoid CB2 receptor: a new target for controlling neural cell survival. Trends in Pharmaceutical Sciences, 28(1), 39-45. Retrieved from http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(06)00267-7.
  • Fishbein, M., Gov, S., Assaf, F., Gafni, M., Keren, O., and Sarne, Y. (2012, September). Long-­term behavioral and biochemical effects of an ultra-­low dose of Δ9-­tetrahydrocannabinol (THC): neuroprotection and ERK signaling. Experimental Brain Research, 221(4), 437-48. Retrieved from http://link.springer.com/article/10.1007%2Fs00221-012-3186-5.
  • Jiang, W., Zhang, Y., Xiao, L., Van Cleemput, J., Ji, S.P., Bai, G., and Zhang, X. (2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. Journal of Clinical Investigation115(11), 3104–3116. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1253627/.
  • Kim, S.H., Won, S.J., Mao, X.O., Jin, K., and Greenberg, D.A. (2006, March). Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Molecular Pharmacology, 69(30), 691-6. Retrieved from http://molpharm.aspetjournals.org/content/69/3/691.long.
  • López Rodríguez, A.B., Siopi, E., Finn, D.P., Marchand-Leroux, C., Garcia-Segura, L.M., Jafarian-Tehrani, M.H., and Viveros, M.P. (2013). CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. Cerebral Cortex. Retrieved from http://cercor.oxfordjournals.org/content/early/2013/08/19/cercor.bht202.abstract.
  • Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S.C., Cascio, M.G., Gutiérrez, S.O., van der Stelt, M., López-Rodriguez, M.L., Casanova, E., Schütz, G., Zieglgänsberger, W., Di Marzo, V., Behl, C., and Lutz, B. (2003, October 3). CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity. Science, 302(5642), 84-8. Retrieved from http://science.sciencemag.org/content/302/5642/84.
  • McDonough, P., McKenna, J.P., McCreary, C., and Downer, E.J. (2014, October). Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. The International Journal of Biochemistry & Cell Biology, 55, 72-8. Retrieved from http://www.sciencedirect.com/science/article/pii/S1357272514002581.
  • Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., Shohami, E. (2001, October). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413(6855), 527-31. Retrieved from http://www.nature.com/nature/journal/v413/n6855/full/413527a0.html.
  • Peripheral neuropathy. (2014, December 2). Mayo Clinic. Retrieved from http://www.mayoclinic.org/diseases-conditions/peripheral-neuropathy/basics/definition/con-20019948.
  • Pryce, G., Ahmed, Z., Hankey, D.J., Jackson, S.J., Croxford, J.L. Pocock, J.M., Ledent, C., Petzold, A., Thompson, A.J., Giovannoni, G., Cuzner, M.L., and Baker, D. (2003, October). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 126(Pt 10), 2191-202. Retrieved from https://academic.oup.com/brain/article/126/10/2191/314489/Cannabinoids-inhibit-neurodegeneration-in-models.
  • Sagredo, O., Garcia-Arencibia, M., de Lago, E., Finetti, S., Decio, A., and Fernandez-Ruiz, J. (2007, August). Cannabinoids and Neuroprotection in Basal Ganglia Disorders. Molecular Neurobiology, 36(1), 82-91. Retrieved from http://link.springer.com/article/10.1007%2Fs12035-007-0004-3.
  • van der Stelt, M., Veldhuis, W.B., Bar, P.R., Veldink, G.A., Vliegenthart, J.F., and Nicolay, K. (2001, September 1). Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity. The Journal of Neuroscience, 21(17), 6475-9. Retrieved from http://www.jneurosci.org/content/21/17/6475.long.
  • Ware, M.A., Wang, T., Shapiro, S., and Collet, J.P. (2015, September 15). Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). The Journal of Pain. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/26385201.
  • Witting, A., Chen, L., Cudaback, E., Straiker, A., Walter, L., Rickman, B., Moller, T., Brosnan, C., and Stella, N. (2006, April 18). Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. PNAS, 103(16), 6362-7. Retrieved from http://www.pnas.org/content/103/16/6362.full.
  • Woodhams, S.G., Sagar, D.R., Burston, J.J., and Chapman, V. (2015). The role of the endocannabinoid system in pain. Handbook of Experimental Pharmacology, 227, 119-43. Retrieved from http://link.springer.com/chapter/10.1007%2F978-3-662-46450-2_7.
  • Xapelli, S., Agasse, F., Sardà-Arroyo, L., Bernardino, L., Santos, T., Ribeiro, F.F., Valero, J., Braganca, J., Schitine, C., de Melo Reis, R.A., Sebastiao, A.M., and Malva, J.O. (2013). Activation of Type 1 Cannabinoid Receptor (CB1R) Promotes Neurogenesis in Murine Subventricular Zone Cell Cultures. PLoS ONE8(5), e63529. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660454/.
  • Zogopoulos, P., Vasileiou, I., Patsouris, E., and Theocharis, S. (2013, April). The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects. Journal of Applied Toxicology, 33(4), 246-64. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1002/jat.2828/full.

You must be at least 18 years or older to purchase medical cannabis
Are you of legal age?

By clicking yes, you agree to it Terms & Conditionss and Privacy Policy

The IntroCann Portal

Please note that the IntroCann Portal is currently available on desktop only. A mobile version of the portal will be available soon.

MOBILE VERSION COMING IN 2021